A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Rintatolimod (Primary) ; Dendritic cell vaccines
- Indications Carcinoma; Mesothelioma; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Dec 2018 Planned End Date changed from 1 Dec 2018 to 18 Feb 2019.
- 26 Dec 2018 Planned primary completion date changed from 18 Aug 2018 to 18 Feb 2019.